Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 1022.85, up by 1.95 points or 0.19% from its previous closing of Rs. 1020.90 on the BSE.
The scrip opened at Rs. 1025.05 and has touched a high and low of Rs. 1028.00 and Rs. 1013.95 respectively. So far 4727 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1071.00 and Rs. 1009.00 respectively. The current market cap of the company is Rs. 102726.43 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.17% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg.
Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone acetate tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.
Fludrocortisone acetate tablets had annual sales of $19.9 million in the United States (IQVIA MAT July 2024). The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
